목적: 당뇨황반부종의 치료에서 트리암시놀론 단독주사와 트리암시놀론 및 베바시주맙 병합 안내 주사의 단기 치료효과를 비교하고자 하였다. 대상과 방법: 당뇨 망막증 이외에 다른 안내 질환이나 OCT상 유리체 황반 견인의 소견은 없으며 황반부종의 이전 치료나 다른 안내 수술을 받지 않은 환자들 중 당뇨황반부종으로 진단받고 치료로 트리암시놀론 4 mg 유리체강 내 단독 주입한 45명 45안(1군)과 트리암시놀론 2 mg과 베바시주맙 1.25 mg 병합 주입한 뒤 1개월 간격으로 2회에 걸쳐 베바시주맙 1.25 mg 유리체강 내 주입 받았던 24명 24안(2군)을 대상으로 주사전과 주 후 1,2,3개월째 시력 및 황반 두께를 측정하여 비교하였다. 결과: 시술 전 시력과 황반 두께는 두 군 사이에 통계적으로 유의한 차이가 없었으며(P>0.05),시술 후 1, 2, 3개월째 두 군 모두 시력호전과 황반 두께 감소를 보였으나(P<0.05), 두 군간의 시력,황반 두께 변화에 있어 통계적으로 유의한 차이는 보이지 않았다(P>0.05). 결론: 당뇨황반부종에 대한 치료로 트리암시놀론 유리체강 내 1회 단독 주입과 트리암시놀론과 베바시주맙의 병합요법은 단기적으로 시력호전과 황반 두께를 감소시키는 효과를 보였으나 두 군간의 치료 효과에 있어서 통계적으로 유의한 차이는 관찰되지 않았으며 향후 반복 주사에 따른 6개월 이상의 장기적인 연구가 추가적으로 필요할 것으로 사료된다.

Purpose: To compare the effect of intravitreal triamcinolone injection with and without bevacizumab for diabetic macular edema. Methods: Of 69 patients (69 eyes) diagnosed with diabetic macular edema without any history of other intraocular disease or intraocular operation, 45 eyes (45 patients) were injected with intravitreal triamcinolone (4 mg) and the remaining eyes (24 patients) were injected with triamcinolone (2 mg) and bevacizumab (1.25 mg). The visual acuity and central macular thickness of treated eyes from both groups was measured using OCT, and these measurements were compared between the two groups. Results: There were no statistical differences between the two groups with respect to baseline data. Central macular thickness (CMT) was reduced in both groups, and BCVA improved in both groups. No significant differences were detected in changes in CMT or BCVA between the two groups. Conclusions: Intravitreal injection of triamcinolone had a beneficial effect on DME in terms of CMT reduction and BCVA improvement. Addition of three consecutive intravitreal bevacizumab injections, however, did not show any significant addictive effect during the follow-up period.

Purpose: To compare the effect of intravitreal triamcinolone injection with and without bevacizumab for diabetic macular edema. Methods: Of 69 patients (69 eyes) diagnosed with diabetic macular edema without any history of other intraocular disease or intraocular operation, 45 eyes (45 patients) were injected with intravitreal triamcinolone (4 mg) and the remaining eyes (24 patients) were injected with triamcinolone (2 mg) and bevacizumab (1.25 mg). The visual acuity and central macular thickness of treated eyes from both groups was measured using OCT, and these measurements were compared between the two groups. Results: There were no statistical differences between the two groups with respect to baseline data. Central macular thickness (CMT) was reduced in both groups, and BCVA improved in both groups. No significant differences were detected in changes in CMT or BCVA between the two groups. Conclusions: Intravitreal injection of triamcinolone had a beneficial effect on DME in terms of CMT reduction and BCVA improvement. Addition of three consecutive intravitreal bevacizumab injections, however, did not show any significant addictive effect during the follow-up period.